Naproxen-PC: a GI safe and highly effective anti-inflammatory
L M Lichtenberger1, J J Romero, E J Dial
1Department of Integrative Biology & Pharmacology, The University of Texas Health Science Center at Houston, Houston, TX, USA. Lenard.M.Lichtenberger@uth.tmc.edu
Inflammopharmacology
|January 14, 2009
Summary
Naproxen-PC, a novel formulation, shows superior gastrointestinal safety and anti-inflammatory effects compared to traditional naproxen in rodent models. This development offers a potentially safer NSAID option.
Area of Science:
- Pharmacology
- Gastroenterology
- Inflammation Research
Background:
- Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used but associated with gastrointestinal (GI) risks.
- Naproxen is noted for a favorable cardiovascular safety profile among NSAIDs.
- Phosphatidylcholine (PC)-associated NSAIDs are being developed for improved GI safety and efficacy.
Purpose of the Study:
- To evaluate the GI safety and anti-inflammatory efficacy of a Naproxen-PC formulation.
- To compare Naproxen-PC with conventional naproxen in established rodent models of GI injury and inflammation.
Main Methods:
- An acute NSAID-induced intestinal bleeding model in rats.
- A chronic inflammation model in rats with pre-existing hindpaw inflammation.
- Assessment of GI protection, hindpaw edema, and prostaglandin E2 (PGE2) levels.
Main Results:
- Naproxen-PC demonstrated superior GI protection compared to naproxen in both acute and chronic rodent models.
- The Naproxen-PC formulation maintained significant anti-inflammatory efficacy, reducing hindpaw edema.
- Reduced PGE2 generation was observed in joint synovial fluid with Naproxen-PC treatment.
Conclusions:
- Naproxen-PC significantly reduces GI injury and bleeding in rodent models.
- The formulation preserves the anti-inflammatory and COX-inhibitory activity of naproxen.
- Naproxen-PC represents a promising NSAID with enhanced GI safety.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:28Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...